ArticleNature communications2025
scRepli-RamDA-seq: a multi-omics technology enabling the analysis of gene expression dynamics during S-phase.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Single-cell sequencing has advanced our understanding of cell-type diversity and heterogeneity. However, existing single-cell multi-omics methods lack the ability to monitor gene expression dynamics during S-phase progression. Here, we introduce single-cell (sc)Repli-RamDA-seq (scRR-seq), a multi-omics method that enables high-resolution DNA replication profiling and full-length total RNA sequencing from the same single cell in a haplotype-specific manner. scRR-seq generates DNA replication and RNA sequencing data comparable to individually obtained scRepli-seq and scRamDA-seq data, respectively. Unlike other scDNA/RNA-seq methods, scRR-seq allows one to tell the S-phase stage of a given cell based on the percentage of the replicated genome derived from scRepli-seq data. This facilitates analysis of gene expression dynamics during S-phase progression, enabling the identification of S-phase progression markers. scRR-seq also detects copy-number variation in non-S-phase cells and outperforms other scDNA/RNA-seq methods in various measures. Taken together, scRR-seq is a robust single-cell multi-omics method with promising potential for comprehensive genome/transcriptome analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.